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PATHOGENIC ROLE OF PHOSPHODIESTERASE TYPE 5 UPREGULATION IN
CARDIAC ISCHEMIA/REPERFUSION INJURY
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Phosphodiesterase Type 5 (PDE5) inhibitors are cardioprotective against
ischemia/reperfusion (I/R) injury. However, it remains uncertain if I/R affects PDE5. We
hypothesized that generation of reactive oxygen species (ROS) during I/R leads to
upregulation of PDE5, which contributes to pathological changes following acute
myocardial infarction (AMI). Adult male ICR mice were subjected to 30 minutes of in
vivo or ex vivo I/R. To examine the role of ROS, a subset of hearts were perfused with 100
µM hydrogen peroxide (H2O2). Expression and activity of PDE5, pPDE5, and cGMP-

xvi

xvii
dependent protein kinase (PKG) were measured by Western blots and spectrophotometric
assay. The results show that ischemia and I/R significantly increased expression of PDE5.
H2O2 had no effect on PDE5 expression and activity but significantly increased PKG
activity. We conclude that acute cardiac ischemia or I/R upregulate PDE5 independent of
oxidant stress in the heart.

Introduction
1.1 Coronary Heart Disease
Coronary heart disease (CHD) is the failure of the coronary circulation to supply
adequate blood to the cardiac muscle and surrounding tissue. The American Heart
Association has determined CHD, the cause of heart attacks and angina, will be the single
leading cause of death in the United States this year just as it has been for the past sixty
years, since 1950. Approximately 425,500 people a year now die of CHD which is nearly
75% of all deaths. In all, about every 25 seconds an American will suffer a coronary event,
and about every minute someone will die from one such attack. In 2010, CHD will cost
the United States $316.4 billion. This total includes the cost of health care services,
medications, and lost productivity.1 Taken together, these indicators constitute a rather
bleak prognosis regarding the overall cardiovascular health of our country’s population and
indicate the urgency with which new medical therapies are needed in order to combat CHD
and reduce its enormous national impact.
As previously mentioned, a heart attack, or acute myocardial infarction (AMI), is a
severe condition caused by CHD. Every year about 785,000 Americans have a first AMI
and 470,000 who have already had one or more will have another. All together AMI
affects an estimated 1.5 million people in the United States annually and is a major cause
of mortality and morbidity worldwide. Over half of the patients with AMI die within one
1
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hour of the event.1 AMI occurs when there is a sudden occlusion of an artery supplying
blood to cardiac muscle, or myocardium, depriving the area of blood and oxygen and
causing dramatic changes in the cellular metabolism and function within this tissue. The
occlusion leading to AMI is usually caused by a buildup of atheromatous plaques on the
walls of the arteries that supply the myocardium. These plaques consist largely of
macrophage cells containing cholesterol and fatty acids, calcium, and a variable amount of
fibrous connective tissue. The resultant lack of blood flow and oxygen is called ischemia
and if maintained for more than a few minutes, there is a loss of contracting myocardium
in the affected area and a resultant increase in the workload on the remaining viable
myocardium. This cardiac overload causes increased energy utilization and a supplydemand imbalance, which lead to cellular necrosis and apoptosis. This subsequently leads
to remodeling and worsening of left ventricular function, and eventually heart failure.2
Since the division of surrounding myocytes cannot replace those that have died from
necrosis and apoptosis, preservation of the myocardium viability after ischemia has
become a major target for therapeutic research.3

1.2 Ischemia/Reperfusion Injury
Following the occurrence of a detrimental occlusion of a coronary artery, it was
shown in 1983 that reperfusion of the vessel was vital to protecting the ischemic
myocardium and salvaging the remaining viable tissue.4 Since that time, the advent of
therapies such as thrombolysis, anti-platelet, and primary angioplasty have provided a
means to reestablish coronary blood flow in the clinical setting. Yet paradoxically, the
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reperfusion therapy itself, following ischemia, results in cardiomyocyte death; an inherent
phenomenon termed ischemia/reperfusion (I/R) injury.
Cell death following I/R has been reported to have features of apoptosis, necrosis,
and autophagy. Apoptosis, or programmed cell death, typically occurs via activation of
caspases that cleave DNA and other cell components. Caspase 9 has been reported to be
activated during ischemia, whereas caspases 8 and 9 are activated during reperfusion.5 A
number of studies have reported that addition of caspase inhibitors reduces infarct size,
suggesting an important role for caspase activation in I/R injury.5-7 Necrosis, or traumatic
cell death, is characterized by cell swelling leading to irreversible rupture of the plasma
membrane, release of cytosolic components, and finally an inflammatory response, which
is an important component of I/R injury. The release of troponin and creatine kinase that
occur during I/R are likely due to necrosis. A rise in cytosolic free Ca2+ as well as the
production of reactive oxygen species (ROS) has been consistently observed in ischemia
and early reperfusion. An increase in Ca2+ and ROS can lead to activation of an inner
mitochondrial large-conductance channel known as the mitochondrial permeability
transition pore (MPTP), causing loss of ATP and mitochondrial function. If a large
number of mitochondria in a cell undergo MPTP, the cell will lose the capacity to make
ATP and ion homeostasis, resulting in necrosis. Finally autophagy is a physiological
mechanism that is used to remove damaged organelles, such as mitochondria or
endoplasmic reticulum, and extensive autophagy can cause cell death. It has been shown
that a decrease in a primary protein mediator of autophagy, beclin1, reduces I/R-mediated

4
autophagy and myocyte death.8 Additionally, an increase in Ca2+, which as stated occurs
during ischemia, has been shown to increase autophagy.9
Ultimately, death following I/R injury appears to be a mixture of apoptotic,
necrotic, and autophagy cell death, and it can have features of all three. The distinction
between the modes of death may not be simple, since recent data suggest that all three
forms can be regulated and are interrelated.10,11 The primary issue is that cell death during
I/R appears to be an active process, causing rapid disruption of heart tissue as shown by the
release of certain cytosolic enzymes and changes in the microscopic structure of the
myocytes. Although the restoration of blood flow proved to be crucial to reduce infarct
size 4, the contradiction of reperfusion injury presents a clinical challenge in finding
therapeutic strategies to limit and reduce I/R insult, thus preserving heart function.

1.3 Ischemic and Pharmacological Preconditioning
In 1986, a phenomenon called ischemic preconditioning (IP) was discovered
involving brief episodes of ischemia applied to the myocardium that would consequently
protect the tissue from subsequent, more prolonged periods of ischemia.12 This incredibly
innovative finding marked the beginning of a new field of research aimed at utilizing this
phenomenon in the protection of the human heart from ischemic heart disease. The
cardioprotective effects of IP have been shown to occur in two different phases or
“windows”. The early phase, referred to as “classic” preconditioning, is primarily
mediated by activation of signaling pathways and posttranslational modification of
proteins. It develops immediately after the IP maneuver and disappears within 1-2
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hours.13,14 The later phase, referred to as the “delayed” window of preconditioning, is
largely mediated by gene induction and protein synthesis. It develops 12 hours later and
lasts up to 96 hours.15-18 Both phases of IP have been shown to reduce infarct size,
contractile dysfunction, arrhythmias, generation of lactate, and rate of fall in ATP.19-21
Over the past 20 years, a great deal has been learned about the signaling pathways
activated by IP and the cellular basis for its protection. The proposed IP mechanisms
include the release of endogenous mediators (such as adenosine, norepinephrine, opioids,
free radicals, and bradykinin),22-26 activation of G protein-coupled receptors and the
phosphatidylinositol 3-kinase (PI3K) pathway (and subsequent downstream targets such as
protein kinase B [Akt], protein 70S6 kinase [p70S6K], protein kinase C [PKC], and
extracellular signal-regulated kinase [ERK]),27-31 opening of mitochondrial KATP
channels,32,33 and synthesis of cytoprotective proteins (including endothelial nitric oxide
synthase [eNOS], inducible nitric oxide synthase [iNOS], cyclooxygenase-2, and heat
shock protein 70).21,34-36
A number of pharmacological activators of IP mechanisms have been given
exogenously to mimic the observed cardioprotective effects. These include adenosine
receptor agonists, nitric oxide donors, bradykinin, anisomycin, cobalt chloride, and
diazoxide; nevertheless, due to the lack of safe and effective drugs, none of the activators
have been translated into clinical use.37 Our laboratory has been at the forefront of this
field of research and, over the course of the last 8 years, a pioneer in inventing the concept
of pharmacological preconditioning with selective phosphodiesterase type 5 (PDE5)
inhibitors. We have shown that drugs such as sildenafil (Viagra), vardenafil (Levitra) and
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tadalafil (Cialis), which are known to enhance erectile function in men, also induce a
powerful cardioprotective effect against I/R in rabbit and mouse hearts,38,39 myocardial
ischemia-induced heart failure,2 and doxorubicin-induced cardiomyopathy in mice.40 In a
series of publications, our laboratory has shown that this preconditioning-like
cardioprotective effect against I/R involved upregulation of eNOS and iNOS, activation of
PKC/ERK, opening of mitochondrial KATP channels, and attenuation of apoptosis by
increasing the B-Cell Lymphoma-2 (Bcl2)/ Bcl-2–associated X protein (bax) ratio.38,39,41-43
Still, as diverse as these mechanisms are, none has shown a direct involvement of PDE5 or
relate to the known pharmacological action of sildenafil on inhibition of PDE5.

1.4 Phosphodiesterase Type 5
The intracellular second messengers cyclic adenosine 3’,5’-monophosphate
(cAMP) and cyclic guanosine 3’,5’-monophosphate (cGMP) both serve vital roles in
cardiovascular regulation by influencing function, gene expression, and morphology.
cAMP is a mediator of many effects of epinephrine on the heart and other tissues while
cGMP mediates nitric oxide (NO) and natriuretic peptide (NP) action.44-53 In 1958 cAMP
was first discovered and this report was soon followed by that of cGMP in 1963.54,55 The
search was then on for researchers to quickly identify enzymes that specifically hydrolyzed
these messengers. Eventually, 11 different 3’,5’-cyclic nucleotide phosphodiesterase
(PDE) isoenzyme families (PDE1-PDE11) were identified and grouped according to their
ability to hydrolyze cAMP and cGMP to the linear 5’-nucleoside monophosphates AMP
and GMP, respectively. This reaction is highly exothermic (> 10 kcal/mol), making it
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essentially irreversible in the cell.56,57 Thus, by producing inert molecules and destroying
the second messenger activity of cyclic nucleotides, PDEs play critical roles in a wide
range of physiological and pathological processes.
PDE5 was originally characterized in the context of an unidentified binding protein
for cGMP and not as a PDE.58 Early descriptions noted a high-affinity cGMP-binding
protein present that did not comigrate with cGMP-dependent protein kinase (PKG)
activity, and at that time PKG was the only known high-affinity binding protein for cGMP.
Within a few years, PDE5 was identified, isolated, and characterized from platelets and
later lung.59-61 It was discovered to be functionally specific for cGMP hydrolysis along
with the presence of high affinity-binding sites for cGMP. At the time, it was initially
thought that PDE5 might be related to the already well understood, light sensitive, cGMPselective PDE found in the eye, which is now known as phosphodiesterase type 6 (PDE6).
Both enzyme families selectively used cGMP compared with cAMP as substrate, both
bound cGMP with high affinity, both were inhibited by many of the same agents, and both
had a very similar size. However, differences in Vmax activities and the lack of regulation
of PDE5 by light suggested that they might be different PDEs. So there existed a
continuing confusion in the scientific literature regarding the molecular identity of the
cGMP-specific PDEs and PDE5 was originally labeled as the “cGMP-binding, cGMPspecific PDE.” The issue was finally resolved when the bovine lung cGMP-binding PDE
was cloned, expressed, and sequenced.62 It was only upon comparison with the previously
published PDE6 sequences that it was entirely clear PDE5 was a distinct gene product.63
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Presently, PDE5 is now known to be dimeric with each monomer approximately 90
to 100 kD in size, depending on species. The carboxyl terminal portion contains the
hydrolyzing catalytic domain of ~230 amino acids, encompassing two zinc-binding motifs
and a catalytic cGMP binding site. The amino terminal portion contains two allosteric
cGMP binding sites of ~90 amino acids each and at least a portion of the dimerization
domain. These N-terminus binding sites are today called regulatory GAF domains of the
enzyme, an acronym derived from the names of the first three classes of proteins
recognized to contain these sequences, i.e., cGMP-binding PDEs, Anabaena adenylyl
cyclase, and Escherichia coli Fh1A.64 The two GAF domains (GAF-A and GAF-B) are
highly homologous, but cGMP binding occurs only to the GAF-A domain (KD < 40 nM) of
PDE5.65 Cyclic nucleotide binding to this domain is greater than 100-fold selective for
cGMP over cAMP, 65 and it has been shown that the allosteric binding of cGMP to the
GAF-A domain stimulates enzyme catalytic activity about 10-fold, while blockage of this
allosteric binding causes inhibited activity.66 Moreover, the affinity of this site for cGMP
is increased by phosphorylation of nearby serine 92, which is just adjacent to the GAF-A
domain, via PKG thereby stabilizing the activated form of PDE5.67,68 Since the original
cloning of the PDE5 cDNA, only one PDE5 gene has been discovered to date, PDE5A,
although 3 variants of the PDE5A mRNA and protein have been identified under the
control of differentially regulated promoters.69-71 PDE5A1, PDE5A2, and PDE5A3 differ
at their N-terminal regions, and all 3 have unique first exons followed by a common
sequence of 823 amino acids. While it has not been proven, it is postulated that the
different promoters for the PDE5 isoforms allow differential control of PDE5 gene
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expression and provide a mechanism for longer term regulation than just the allosteric
binding or phosphorylation previously mentioned.
Interestingly, despite it being one of the first of the 11 PDE families found to be
cGMP specific, PDE5 received little notoriety or attention until studies discovered its role
as a regulator of vascular smooth muscle tone.72-74 By the mid 1980’s, pharmacologists at
Pfizer research laboratories were working on an antihypertension drug and postulated that
a selective cGMP PDE inhibitor might relax arteries and lower blood pressure by
augmenting intracellular cGMP. In screening for agents that inhibited cGMP hydrolysis
but not cAMP, they found a cGMP PDE selective agent, UK-92 480, which was first
targeted clinically at angina pectoris. The tests proved to be disappointing, with very little
cardiovascular impact, however patients reported “side effects” at high doses, which
included penile erections. Pfizer shifted its indication to treatment for erectile dysfunction
and sildenafil (Viagra) was created in 1998 as the first isozyme-selective PDE inhibitor in
wide clinical use. This “urological detour” away from investigating direct cardiovascular
applications of PDE5 inhibition helps to explain why it took considerable time before
focus was diligently applied to PDE5 with respect to cardiovascular disease and regulation.

1.5 PDE5 and Cardiac Function
The primary effect of PDE5 activity is to hydrolyze cGMP and thus lower its
intracellular levels. In turn, cGMP can influence other PDEs responsible for regulating
cAMP by binding to their allosteric or catalytic sites. Phosphodiesterase type 2 (PDE2) is
expressed in myocytes and has regulatory GAF domains that can bind cGMP and in turn
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enhance cAMP hydrolysis.75,76 Alternatively, cGMP can competitively bind to the
catalytic site of phosphodiesterase type 3 (PDE3). This enzyme binds both cAMP and
cGMP at high affinity and similar Km but has a Vmax for cAMP 10-fold greater, conferring
catalytic specificity. At higher levels cGMP may inhibit PDE3 hydrolysis, resulting in
enhanced cAMP which influences cardiac rhythm (chronotropy), contractile force
(inotropy) and relaxation (lusitropy) while additionally playing a role in platelet
aggregation and endothelial cell permeability (Fig. 2).77-81
Still, of vital importance is cGMP’s ability to stimulate PKG and this is presently
thought to be the major effect of PDE5 activity on vessels and the heart. As previously
mentioned, the classical role of PDE5 is in modulation of vascular smooth muscle
contraction. In this case, cGMP is generated either from soluble guanylate cyclase (sGC)
present in the cytosol (triggered by NO) or from particulate guanylate cyclase (pGC)
present at the plasma membrane (triggerd by NP). The generated cGMP activates PKG
which then via several mechanisms causes muscle relaxation. These mechanisms involve
decreasing intracellular free calcium concentrations,82,83 reducing calcium sensitization,8486

and regulating thin filament proteins (Fig. 1).87-94 Thus PDE5 functions, by catalyzing

the hydrolysis of cGMP, to antagonize all of these observed effects and intriguing
emerging evidence is beginning to show this role may be more significant in cardiac
function than originally considered.
The presence of PDE5 within the heart has been a contentious issue with many
positive and negative findings.95-100 Our laboratory was able to detect PDE5 gene and
protein expression in the mouse heart and cardiomyocytes by RT-PCR, immunofluorescent
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staining, and Western blotting.43 Still, despite this discovery combined with other early
evidence of myocardial PDE5 gene expression,69,101 its protein synthesis and enzyme
activity are rather low compared with other tissues such as lung, and were traditionally
thought to be physiologically insignificant.99,102 In spite of this, more recent studies have
reported evidence of both detectable PDE5 mRNA and protein expression in isolated
cardiomyocytes, as well as the physiologic effects of PDE5 inhibition in myocytes and
whole heart.43,96,97,103 There is also growing evidence indicating the importance of
compartmentation in cyclic nucleotide PDE modulation.104 Myocytes transfected with a
cGMP-sensitive Ca2+ reporter channel recorded increased membrane cGMP induced by NP
stimulation that was completely unchanged by concomitant PDE5 inhibition. This
contrasted to the signal generated by NO donors, which sildenafil enhanced.105 Therefore,
it seems that PDE5 exerts a specific spatiotemporal control on the pool of intracellular
cGMP synthesized by sGC but not that generated by pGC. Additionally, although the
levels of PDE5 in cardiomyocytes are rather low, newer data suggest its regulatory effects
may be due to it being primarily localized to the Z-line in healthy animals, while under
pathological conditions it is dispersed throughout the cell.43,96,103,106
The level of PDE5 within the heart appears to be influenced by the occurrence of
heart disease and it confers targeted regulation of stress responses despite having little
influence on basal function. PDE5 expression is reportedly increased in human and animal
models of right ventricular hypertrophy.107 In these studies, PDE5 inhibition significantly
increased contractility, cGMP, and cAMP in hypertrophied right ventricles but not in
normal right ventricles. Studies have also shown that cGMP catabolism by PDE5 is
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increased in chamber and myocyte hypertrophy which can be suppressed by the
administration of PDE5 inhibitors.108 Increased PDE5 expression has also been shown in
left ventricles of humans with end-stage ischemic and dilated cardiomyopathy. 109,110
These studies additionally demonstrated that a cardiomyocyte-specific overexpression of
PDE5 in transgenic mice predominately localized to Z-bands and predisposed them to
adverse left ventricle remodeling following AMI. Along these same lines, it has been
reported that myocyte hypertrophy is blunted by PDE5 gene silencing with small hairpin
RNA (shRNA).106 PDE5 upregulation has also been cited in a number of other chronic
cardiovascular diseases including pulmonary hypertension and congestive heart
failure.111,112 Still, pathological regulation over PDE5 is scantily dealt with in the existing
literature and its behavior has not been studied in more acute models of heart disease like
I/R.

1.6 PDE5 and Reactive Oxygen Species
Aerobic organisms create energy needed to fuel biological functions by oxidative
phosphorylation, a process which involves the transport of hydrogen ions across the inner
mitochondrial membrane by means of the electron transport chain. In the electron
transport chain, electrons are passed through a series of proteins via redox reactions. The
last destination for an electron along this chain is an oxygen molecule. Normally the
oxygen is reduced to produce water, but sometimes oxygen is instead prematurely and
incompletely reduced to create reactive oxygen species (ROS) such as superoxide radicals
(·O2-) and hydrogen peroxide (H2O2).113-117 This "physiologic" generation of ROS is

13
normally inactivated by endogenous antioxidant scavenger mechanisms present within the
cells.118
During ischemia, ROS are generated within and can lead to damage to the electron
transport chain of mitochondria.119-121 Upon reperfusion, with the return of oxygen, a large
burst of ROS is seen.122-124 This increase in ROS during ischemia and reperfusion is
thought to be due to damage to electron transport chain components resulting in inefficient
transfer of electrons. This toxic ROS overproduction can damage or deplete endogenous
antioxidants and possibly contribute to irreversible damage of mitochondrial function and
consequently impaired recovery of physiological function and cell death.125-130
Recent studies have led to consideration of a correlation between ROS and PDE5
expression/activity. It has been demonstrated that exposing fetal pulmonary artery smooth
muscle cells (FPASMCs) to hyperoxia leads to a decreased intracellular cGMP response,
increased PDE5 phosphorylation, mRNA and protein expression, as well as increased
cGMP hydrolytic activity. Treatment of normoxic FPASMCs with exogenous H2O2
induced PDE5 expression and activity, suggesting that ROS potentially mediate the PDE5enhancing effects of hyperoxia in FPASMCs. Additionally, treatment with a chemical
antioxidant, N-acetyl-cysteine, was sufficient to block the increases in PDE5 expression
and activity.131 An extremely current work has shown that in mice, following transverse
aortic constriction (TAC)-induced congestive heart failure (CHF), an increase of
myocardial PDE5 expression positively correlated with the levels of oxidative stress
markers 3’-nitrotyrosine and 4-hydroxynonenal expression. The superoxide dismutase
(SOD) mimetic M40401 attenuated oxidative stress and blunted PDE5 expression and
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activity as well as CHF, while increased oxidative stress in SOD3 knockout mice
exacerbated the increase in PDE5 expression and CHF following TAC.110 These studies
are intriguing and lend credence to the possibility that oxidative stress could regulate PDE5
within the heart.

1.7 Rationale of the Present Study
The purpose of the current investigation was to identify the role of PDE5 within the
heart and specifically its response to acute cardiac I/R injury. We hypothesized that the
detrimental events of ischemia and reperfusion lead to a deleterious upregulation of PDE5,
which is connected to the overproduction of ROS and contributes to the adverse cardiac
stress response and pathological changes following AMI. Of particular interest was
defining PDE5 within the signaling mechanisms underlying the already proven
cardioproctective action of selective PDE5 inhibitors.
To test this hypothesis we used a murine model of in vivo regional I/R where we
occluded the left anterior descending coronary artery (LAD) for 30 minutes and reperfused
the heart for varying durations of time. We additionally used a Langendorff isolated
perfused mouse heart model to administer 30 minutes of global ischemia and varying
durations of reperfusion. This ex vivo model also allowed us to examine the effects of
exogenous oxidant stress upon the heart via perfusion with the oxygen radical generator
H2O2.
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Figure 1: General scheme for the role of PDE5 in cGMP-signaling pathways.
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Figure 2: Overview of PDE5 in cardiac muscle.
Inhibition of PDE5 leads to a rise in intracellular cGMP and activation of PKG. This may
result in muscle relaxation and antihypertrophic effects. The rise in cGMP may potentiate
cAMP-mediated signaling in cardiac muscle by inhibition of PDE3 or reduce cAMPmediated signaling by stimulation of PDE2

Materials and Methods
2.1 Animals
Adult male ICR mice weighing 35.5 ± 1.2 g were supplied by Harlan Sprague
Dawley Co. (Indianapolis, IN). All animal experimental preparations and protocols were
conducted under the guidelines on humane use and care of laboratory animals for
biomedical research published by the U.S. National Institutes of Health (NIH Publication
No. 85-23, revised 1996). The experimental protocols were approved by the Institutional
Animal Care and Use Committee of Virginia Commonwealth University.

2.2 Drugs and chemicals
Unless otherwise specified, all the chemicals were purchased from Sigma-Aldrich
(St. Louis, MO). Chemicals include those for preparing the K-H buffer in Langendorff
isolated heart experiments (i.e. NaCl, NaHCO3, CaCl2, KCL, KH2PO4, MgSO4, glucose,
EDTA) as well as H2O2. Sildenafil is a pure solid powder and was kindly provided by
Pfizer, Inc. (New York, NY) and dissolved in water. Pentobarbital sodium was the
anesthetic used for all the surgeries and was supplied by Ovation Pharmaceuticals, Inc.
(Deerfield, IL).
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2.3 Myocardial Infarction
Prior to surgery, adult ICR mice were weighed and anesthetized with pentobarbital sodium
(70 mg/kg, ip). They were intubated orotracheally and ventilated on a positive-pressure
rodent ventilator (Harvard apparatus), set at 133 cycles/min and a tidal volume of 0.2 ml.
A left thoracotomy was performed at the fourth intercostal space in order to expose the
heart. Upon visualizing the LAD under a magnifier or microscope, a 7.0 silk ligature was
passed underneath the artery and a piece of polyethylene (PE)-10 tubing was placed on the
artery. Ischemia was induced by tying the PE-10 tubing onto the artery with the ligature.
The tubing was removed after 30 minutes of ischemia in order to reperfuse the vessel and
the silk ligature was left in place to mark the risk area for ischemia. A 5.0 silk suture was
used to close the chest. The animals were extubated and injected intramuscularly with
analgesic (Buprenex; 0.02 mg/kg) for pain reduction, and antibiotic (gentamicin; 0.7
mg/kg) to prevent infection. Afterward, the animals were allowed to recover. Following
the desired length of reperfusion each mouse was again anesthetized with pentobarbital
sodium (100 mg/kg, ip). The chest was then opened at the sternum, and the heart was
rapidly removed from the thorax and harvested at the different time points (Fig. 3). The
hearts were rinsed in PBS to remove blood, snap frozen in liquid nitrogen, and
immediately stored in -80°C conditions until further use for biochemical/molecular assays.

2.4 Measurement of infarct size
Results were obtained from my lab group involving the use of PDE5 inhibitors and their
effect on the subsequent infarct size following ligation. Directly relevant to this project

19
was the protocol in which adult ICR mice received an injection of saline (0.2 mL, ip) or
sildenafil (0.71 mg/kg in 0.2 mL saline, ip) 1 hour before undergoing 30 minutes of
ischemia followed by 24 hours of reperfusion (Fig. 4). At the end of each experiment, the
hearts were washed of blood, and ~2 mL of 10% Evans blue dye was injected as a bolus
into the aorta until most of the heart turned blue. The heart was then washed with saline to
remove the excess Evans blue. Finally, the heart was frozen at -20°C. The frozen hearts
were then cut by hand using a surgical blade parallel to the atrioventricular groove, into 6
to 8 transverse slices of approximately equal thickness (~1mm). The heart slices were
incubated in a 10% 2, 3, 5-triphenyl tetrazolium chloride (TTC, Sigma) solution for 30
minutes at room temperature. In normal myocardium, TTC is converted by dehydrogenase
enzyme to a dark red formazan pigment. On the other hand, infracted myocardium, due to
loss of dehydrogenase enzyme following cell membrane rupture, does not take up TTC
stain and remains a pale color. After staining, the TTC was removed and replaced with
10% formaldehyde for additional 2-4 hours to fix the heart slices. Thereafter, the heart
slices were digitally imaged and the areas of infarcted tissue, the risk zone, and the whole
left ventricle were measured using computer morphometry (Bioquant98). The risk area
was calculated as total ventricular area minus the area of the cavities. The infarct size was
calculated as a percentage of the risk area (Fig. 5).

2.5 Langendorff isolated heart preparation
Prior to surgery, adult ICR mice were weighed and anesthetized deeply with pentobarbital
sodium. Anesthesia was prepared by mixing 0.2 mL of heparin to protect the heart against
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microthrombi, 0.4mL of pentobarbital, and 0.2 mL saline. Each mouse was injected
intraperitoneally with 0.2 mL of anesthesia (100 mg/kg). The chest was then opened at the
sternum, and the heart was rapidly removed from the thorax and placed in a small dish
containing ice-cold Krebs-Henseleit (K-H) buffer and heparin (0.1 mL per dish), where it
was trimmed of excessive tissue and fat. The aortic opening was exposed and quickly
cannulated on a 20-gauge blunt needle and double loop tied using a 5.0 silk suture. The
heart was then retrogradely perfused at a constant pressure of 55 mmHg through the aorta
in a non-recirculating Langendorff apparatus (Fig. 6) with modified K-H buffer [containing
(in mM) 118 NaCl, 24 NaHCO3, 2.5 CaCl2, 4.7 KCL, 1.2 KH2PO4, 1.2 MgSO4, 11
glucose, and 0.5 EDTA]. The K-H solution was pre-filtered by a micro-filter (Millipore
Corp.) with a pore size of 0.45 μm diameter, and was continuously gassed with 95% O2 +
5% CO2 (pH ~ 7.4). The perfusion solution was warmed to 40 ºC through a water-jacketed
glass cylinder/heat exchanger system with a warming/cooling bath and automatic thermal
controller (Brinkmann) and was constantly circulated by a varistaltic water pump
(Manostat). The solution was warmed to 40 ºC to compensate for any heat loss
experienced as the buffer circulates through the Langendorff apparatus. The ambient
temperature around the heart was also kept at 37 ± 0.2 ºC throughout the experiment using
a 100 Watt heating lamp. A digital thermometer (VWR) continuously monitored the air
temperature around the heart. Hearts were retrogradely perfused for the control, ischemia
alone, or ischemia plus reperfusion groups at the different time points shown (Fig. 7). For
ischemia and reperfusion, following the 30 minute stabilization period, the hearts were
subjected to a 30 minute no-flow normothermic global ischemia by closing off a stopcock
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connected to the aortic cannula and reperfusion was started by reopening the stopcock of
the aortic cannula and continued for 30 minutes. In separate experiments, H2O2 (100 µM)
was administered for 10 or 30 minutes via a syringe pump to the heart in conjunction with
K-H buffer (Fig. 8). Following 20 and 30 minute stabilization periods, respectively, the
hearts were subjected to H2O2 perfusion by opening a side-port of the stopcock connected
to the aortic cannula. Once the appropriate time (10 or 30 minutes) of infusion had been
achieved the stopcock was switched back to perfusion solely with K-H buffer for 30
minutes. Following treatment in both experiments, the hearts were then cut off of the
Langendorff apparatus removing the atria, and snap frozen in liquid nitrogen and
immediately stored in -80°C conditions until further use.

2.6 Protein extraction
Adult ICR mice hearts were snap frozen in liquid nitrogen and immediately stored at –
80°C following both myocardial infarction and Langendorff isolated heart protocols. Each
heart sample was crushed using a mortar and pestle. Liquid nitrogen was added as needed
during this process to prevent the tissue sample from thawing. Once the sample was
crushed into a fine powder, 1.0 mL of ice-cold lysis buffer [containing (in mM) 20 Tris*
HCL pH 7.4, 150 NaCl, 1 EDTA, 1 EGTA, 0.2 PMSF, 0.2 Na3VO4, and 5 βMercaptoethanol, with protease inhibitor cocktail (Pierce) and phosphatase inhibitor
cocktail (Pierce) (10 μL of each inhibitor per mL of buffer used)] was added to each
sample tube. The samples were then homogenized with a Glas-Col® Tissue Homogenizing
System, transferred to Eppendorff tubes, and sonicated with a Heat Systems Inc. Sonicator
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Ultrasonic Processor XL. Each sample was kept on ice for an additional 30 minutes before
being centrifuged at 12,000 G (Eppendorf Centrifuge 5810R) at 4°C for 15 minutes. The
supernatant was separated from the pellet, divided up into 3 aliquots, purified over Zeba
Desalting Spin Columns (Thermo Fisher Scientific, Rockford, IL) and stored in –80°C
conditions for further analysis. Protein content of each heart sample was determined by
using 10 mg of bovine serum albumin (BSA, Sigma-Aldrich) in 10mL of distilled water,
forming a BSA stock solution. Taking 1 mL of the solution and adding it to 19 mL of
distilled water diluted this stock solution. This second solution was used to establish a
standard curve by adding different amounts of the BSA solution, water and protein assay
dye (Bio-Rad Laboratories, Inc., Hercules, CA). To determine the protein concentration of
our collected samples, 2 μl of each heart tissue sample were added to 798 μl of water along
with 200 μl of protein assay dye before protein concentration was determined by
performing the Bradford assay using a SmartSpecTM 3000 spectrophotometer (BioRad).132

2.7 Western Blot
Protein samples were combined with an equal volume of a loading buffer solution made by
mixing 25 μl of Laemmli sample buffer (Bio-Rad), and 475 μl β-mercaptoethanol (BioRad). The samples were boiled for 5 minutes and centrifuged for 20 seconds at 14,000
rpm at room temperature before being loaded into each well on polyacrylamide gels (BioRad). A protein marker (Bio-Rad) was also used for better identifying the molecular
weight of the target protein. The gels were electrophoresed by a Bio-Rad energy pack for
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1 hour at 180 volts using a running buffer [1X Tris/glycine/sodium dodecyl sulfide (TGS)].
These electrophoresed proteins were trans-blotted from the gel to nitrocellulose
membranes (Bio-Rad) for 90 minutes at 400 mA in 4°C using a transfer buffer (700 mL
water, 200 mL methanol, 100 mL 10X TGS). After transfer, the nitrocellulose membranes
were placed for 1 hour in blocking solution [5% nonfat dry milk (Bio-Rad), in 1X Trisbuffered saline (Bio-Rad) and 0.05% Tween-20 (Bio-Rad) wash (1X TBST)] at room
temperature to inhibit nonspecific binding. Subsequently, the membranes were incubated
with primary antibodies on a rocking platform overnight in a 4°C cold room at the
appropriate dilution in 5% milk in 1XTBST (1:500 for PDE5A [rabbit polyclonal] [Santa
Cruz Biotechnology, Inc., Santa Cruz, CA], 1:1000 for α-Tubulin [goat polyclonal] [Santa
Cruz], 1:500 for phosphorylated-vasodilator-stimulated phosphoprotein [pVASP][Ser239]
[rabbit polyclonal] [Cell Signaling Technology, Inc., Boston, MA], 1:500 for
phosphorylated-phosphodiesterase type 5 [pPDE5][Ser92] [rabbit polyclonal] [Fabgennix,
Inc., Frisco, TX], and 1:1000 for vasodilator-stimulated phosphoprotein [VASP] [rabbit
polyclonal] [Cell Signaling]). After being washed, the blots were incubated with antirabbit (GE Healthcare, Buckinghamshire, UK) or anti-goat (Santa Cruz) secondary
antibody conjugated to horseradish peroxidase at a 1:2000 dilution in 5% milk in 1XTBST
on a rocking platform for 1 hour at room temperature. Membranes were then washed, and
the bands were visualized via enhanced chemiluminescence (PerkinElmer, Waltham, MA)
and film in a dark room which was subsequently developed by a film processor (Kodak,
Rochester, NY). The bands of proteins were quantified using the Image J (Image
Processing and Analysis in Java) computer program. Expression for PDE5 and pPDE5

24
were normalized to α-Tubulin expression while expression for pVASP was normalized to
VASP expression.

2.8 Activity Assay
Protein samples were assayed for cGMP hydrolytic activity using a commercially available
spectrophotometric cyclic nucleotide phosphodiesterase assay kit (Biomol, Plymouth
Meeting, PA). The basis for the assay is the cleavage of cGMP by a cyclic nucleotide
phosphodiesterase, such as PDE5, followed by the release of free phosphate by a 5’nucleotidase from Crotalus atrox venom. The free phosphate is quantified using the
Biomol Green reagent (Biomol) in a modified Malachite Green assay.133,134 The reactions
were mixed in a 96-well plate, and started in a timed fashion by addition of
phosphodiesterase. Each sample was read in four wells, two without sildenafil and two
with sildenafil (250 nM), to determine PDE5 specific cGMP hydrolytic activity. The
samples were then incubated at 30°C for 30 minutes and stopped in a timed fashion by
addition of the Biomol Green reagent (Biomol). The samples were incubated with the
Biomol Green reagent at room temperature for 20 minutes. Results were measured using a
SpectraMax Multi-Mode Microplate Reader (Molecular Devices, Sunnyvale, CA) at 620
nm wavelength and compared to a standard curve generated with GMP and 5’nucleotidase. The difference between the pmol cGMP hydrolyzed per µg total protein per
minute without sildenafil and the pmol cGMP hydrolyzed per µg total protein per minute
with sildenafil represents the PDE5 specific cGMP hydrolytic activity. Results are shown
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as the PDE5 specific pmol cGMP hydrolyzed per µg total protein per minute for each
sample.

2.9 Cytotoxicity Assay
In the Langendorff isolated heart preparations, the leakage of lactate dehydrogenase (LDH)
into the isolated mouse heart coronary effluent was assayed spectrophotometrically using a
commercially available kit (BioVision, Mountain View, CA). The intracellular enzyme
LDH is a stable cytoplasmic enzyme present in all cells and is rapidly released upon
damage to the plasma membrane. The basis for the assay is a coupled enzymatic reaction
whereby LDH oxidizes lactate to pyruvate which then reacts with tetrazolium salt to form
formazan which can be quantified by a formazan dye. Thus the increase in the amount of
formazan produced directly correlates to the increase in the number of lysed cells and
functions as a way of monitoring cardiomyocyte death. The coronary effluent was
collected from the hearts at 1 minute prior to the global ischemia or H2O2 as well as 5, 10,
20, and 30 minutes during the reperfusion period (Fig. 7 & 8). The reactions were mixed
in a 96-well plate, and started in a timed fashion by addition of 100µL of reaction mixture
to 100µL of coronary effluent. Each sample was prepared in duplicate and incubated at
room temperature for 30 minutes while being protected from light. Results were measured
using a SpectraMax Multi-Mode Microplate Reader (Molecular Devices, Sunnyvale, CA)
at 490 nm wavelength and normalized against the individual coronary flow rate.
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2.10 Data analysis and statistics
For each experiment, data from samples were calculated and expressed as means ± SEM.
The significance of differences between experimental conditions was determined by
unpaired t-tests. P < 0.05 was considered to be statistically significant.
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Figure 3: Myocardial infarction protocol for ischemia and I/R.
Experimental protocol for studies of PDE5 following Ischemia and I/R. Arrows indicate
the time points for performance of surgical procedures.
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Figure 4: Protocol for studies of sildenafil therapy on myocardial infarction.
Experimental protocol for sildenafil administration prior to myocardial infarction.
Sildenafil (0.71 mg/kg) was administered intraperitoneally 1 hour before left anterior
descending coronary aretery (LAD) ligation. Arrows indicate the time points for
saline/sildenafil treatment and performance of surgical procedures.
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Risk Area (Pink Line)
Viable Tissue (Red)
Right Ventricle
Non-Risk Area (Blue)
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Infarcted Tissue (Pale)
Left Ventricle (Red Line)

Figure 5: Representative section of mouse heart.
This cross section shows the criteria used to determine the risk area, non-risk area,
infracted tissue, cavity area, and viable tissue. The risk area was calculated as total
ventricular area minus the area of the cavities. The infarct size was calculated as a
percentage of the risk area.
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Figure 6: Illustrative description of the Langendorff isolated perfused heart system.
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Figure 7: Langendorff isolated heart protocol for ischemia and I/R.
Experimental protocol for studies of PDE5 following ischemia and I/R. Arrows indicate
the time points for performance of surgical procedures and minute marks show time points
for collection of coronary effluent.
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Figure 8: Langendorff isolated heart protocol for oxidant stress with 100 µM H2O2.
Experimental protocol for studies of PDE5 following 10 minutes (A) or 30 minutes (B) of
oxidant stress by perfusion with the oxygen radical generator H2O2. Arrows indicate the
time points for performance of surgical procedures and minute marks show time points for
collection of coronary effluent.
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Results
3.1 Exclusions
Among the hearts used in the experimental protocols, approximately 25% were
excluded due to one or more of the following reasons: death during any portion of the
surgical procedure, damage to the aorta during cannulation, longer cannulation time
(greater than 3 minutes), excessive coronary flow, and arrhythmic heart beat during the
stabilization period.

3.2 Infarct size following Sildenafil preconditioning
The selective PDE5 inhibitor sildenafil has been shown to have a cardioprotective
effect in the mouse heart model by results obtained from my lab group. Mice were divided
into two experimental groups and sextuplicate samples were obtained following the
surgical protocol for saline or sildenafil treatment, respectively (Fig. 4). Myocardial
infarct size was significantly reduced from 41.8±1.5% in saline-treated control mice to
15.8±1.3% in sildenafil-treated mice (Fig. 9A, Fig. 10A & B). Infarct size was calculated
as a percentage of total risk area, a measured area that did not vary between the two
experimental groups (Fig. 9B).

34
3.3 In vivo ischemia and I/R
Mice were divided into three experimental groups and triplicate samples of the
whole heart were harvested following 30 minutes of ischemia, 30 minutes of ischemia plus
12 hours reperfusion, or 30 minutes of ischemia plus 24 hours of reperfusion (Fig. 3).
Cardiac PDE5 expression: The expression of PDE5 was confirmed via Western blot
analysis (Fig. 11). All three treatment groups elicited a significant upregulation of PDE5
protein when compared to their respective control sham operated groups (Fig. 12, Table 1).
Interestingly, while this upregulation of PDE5 protein surged immediately following 30
minutes of ischemia, there was a decrease at 12 hours of reperfusion followed by a
subsequent increase at 24 hours of reperfusion (Fig. 13).
Cardiac PDE5 enzyme activity: The cGMP hydrolytic activity was confirmed via
spectrophotometric analysis. All three treatment groups showed a trend towards increase
in the activity of PDE5 enzyme when compared to the respective control sham operated
group (Fig. 14, Table 1).
Cardiac pPDE5 expression: The expression of pPDE5 was confirmed via western blot
analysis (Fig. 15). After careful densitometry measurement of completed western blots, no
appreciable difference in the phosphorylation state of PDE5 was observed between any of
the time points (Fig. 16, Table 1).
Cardiac pVASP expression: The expression of pVASP was confirmed via western blot
analysis (Fig. 17). Densitometric scanning showed no appreciable difference in the
phosphorylation state of VASP versus total VASP between any of the time points (Fig. 18,
Table 1).
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3.4 Ex vivo ischemia and I/R
Mice were divided into three experimental groups and quadruplicate samples of the
whole heart were harvested following 90 minutes of normoxic perfusion, 30 minutes of
global ischemia, or 30 minutes of global ischemia plus 30 minutes of reperfusion (Fig. 7).
Cytotoxicity: The time course of LDH release into the coronary effluent during the preischemic stabalization and reperfusion periods was measured by spectrophotometric
analysis. Reperfusion of the isolated heart following ischemia caused a significant
increase in the leakage of LDH (Fig. 19).
Cardiac PDE5 expression: The expression of PDE5 was confirmed via western blot
analysis (Fig. 20). The treatment groups elicited a significant increase in the upregulation
of PDE5 protein when compared to their respective control of 90 minutes normoxic
perfusion (Fig. 21, Table 1).
Cardiac PDE5 enzyme activity: The cGMP hydrolytic activity was confirmed via
spectrophotometric analysis. Both treatment groups trended to increase in the activity of
PDE5 enzyme when compared to the respective control normoxic perfusion group (Fig.
22, Table 1).
Cardiac pPDE5 expression: The expression of pPDE5 was confirmed via western blot
analysis (Fig. 23). No appreciable difference in the phosphorylation state of PDE5 was
observed between any of the time points (Fig. 24, Table 1).
Cardiac pVASP expression: The expression of pVASP was confirmed via western blot
analysis (Fig. 25). Interestingly, treatment of 30 minutes of global ischemia elicited a
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significant increase in the upregulation of pVASP protein when compared to the respective
normoxic perfusion, however no appreciable difference in the phosphorylation state of
VASP versus total VASP was observed when the 30 minutes of global ischemia was
followed by 30 minutes of reperfusion (Fig. 26, Table 1).

3.5 10 minutes of ex vivo oxidant stress
Mice were divided into two experimental groups and sextuplicate samples of whole
mouse heart were harvested following 60 minutes of normoxic perfusion or 10 minutes of
perfusion with H2O2 plus 30 minutes of reperfusion (Fig. 8a).
Cytotoxicity: The time course of LDH release into the coronary effluent during the
stabalization and reperfusion periods was measured by spectrophotometric analysis.
Perfusion of the isolated heart with H2O2 did not cause a significant increase in the leakage
of LDH (Fig. 27).
Cardiac PDE5 expression: The expression of PDE5 was confirmed via western blot
analysis (Fig. 28). After careful densitometry measurement of completed western blots, no
appreciable difference in the expression of PDE5 was observed (Fig. 29, Table 1).
Cardiac PDE5 enzyme activity: The cGMP hydrolytic activity was confirmed via
spectrophotometric analysis. Oxidant stress had little effect on the activity of PDE5
enzyme when compared to the respective control normoxic perfusion group (Fig. 30, Table
1).
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Cardiac pPDE5 expression: The expression of pPDE5 was confirmed via western blot
analysis (Fig. 31). No appreciable difference in the phosphorylation state of PDE5 was
observed between groups (Fig. 32, Table 1).
Cardiac pVASP expression: The expression of pVASP was confirmed via western blot
analysis (Fig. 33). After careful densitometry measurement of completed western blots, no
appreciable difference in the expression of pVASP was observed (Fig. 34, Table 1).

3.6 30 minutes of ex vivo oxidant stress
Mice were divided into two experimental groups and duplicate samples of whole
hearts were harvested following 90 minutes of normoxic perfusion or 30 minutes of
perfusion with H2O2 plus 30 minutes of reperfusion (Fig. 8b).
Cytotoxicity: The time course of LDH release into the coronary effluent of isolated mouse
hearts during the stabalization and reperfusion periods was measured by
spectrophotometric analysis. Perfusion of the isolated heart with H2O2 caused a significant
increase in the leakage of LDH (Fig. 35).
Cardiac PDE5 expression: The expression of PDE5 was confirmed via western blot
analysis (Fig. 36). Densitometric analysis of blots showed no appreciable difference in the
expression of PDE5 (Fig. 37, Table 1).
Cardiac PDE5 enzyme activity: The cGMP hydrolytic activity was confirmed via
spectrophotometric analysis. Oxidant stress had little effect on the activity of PDE5
enzyme when compared to the respective control normoxic perfusion group (Fig. 38, Table
1).
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Cardiac pPDE5 expression: The expression of pPDE5 was confirmed via western blot
analysis (Fig. 39). No appreciable difference in the phosphorylation state of PDE5 was
observed between groups (Fig. 40, Table 1).
Cardiac pVASP expression: The expression of pVASP was confirmed via western blot
analysis (Fig. 41). 30 minutes of oxidant stress by H2O2 perfusion elicited a significant
upregulation of pVASP protein expression when compared to the respective normoxic
perfusion (Fig. 42, Table 1).
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Figure 9: Sildenafil preconditioning reduces infarct size
Adult male ICR mice were treated with either saline or sildenafil intraperitoneally 1 hour
before being subjected to 30 minutes of left anterior descending coronary artery ligation
followed by 24 hours of reperfusion. Infarct size was significantly reduced by sildenafil
(A), while risk area was calculated as a percentage of total area and was similar in both
groups (B).
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Figure 10: Representative digital images of stained heart slices
Heart slices were stained with Evans blue dye, TTC, and fixed with formalin. Unaffected,
non-risk area shows dark blue, viable risk area tissue remains red, and infarcted tissue
appears pale white. The saline control heart (A) has a much larger infarcted area when
compared to the sildenafil-treated heart (B), which shows healthy myocardium and little
infarcted tissue.
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Figure 11: Ischemia and I/R upregulate cardiac expression of PDE5 in vivo
Adult male ICR mice were subjected to 30 minutes of left anterior descending coronary
artery ligation alone (A), or followed by 12 hours of reperfusion (B), or 24 hours of
reperfusion (C). Following treatment hearts were harvested and equal amounts of whole
heart homogenate protein were resolved by SDS-PAGE and analyzed by Western blotting
with antibody against PDE5 (98 kDa). Blots were reprobed for α-Tubulin (55 kDa) to
demonstrate equal protein loading.
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Figure 12: Ischemia and I/R significantly increase cardiac PDE5 protein expression in
vivo.
Adult male ICR mice were subjected to 30 minutes of left anterior descending coronary
artery ligation alone(A), or followed by 12 hours of reperfusion (B), or 24 hours of
reperfusion (C). Western blot densitometry measurements were calculated as a ratio of
PDE5 to α-Tubulin which is significantly increased by both ischemia and I/R when
compared to respective sham controls. Bar graphs represent the mean ± SEM.
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Figure 13: PDE5 protein expression varies with duration of reperfusion in vivo.
In terms of the % increase from respective sham controls, the upregulation of PDE5
protein peaked immediately following 30 minutes of ischemia, with a decrease at 12 hours
of reperfusion followed by a subsequent increase at 24 hours of reperfusion.
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Figure 14: Ischemia and I/R trend to increase cardiac PDE5 protein activity in vivo.
Adult male ICR mice were subjected to 30 minutes of left anterior descending coronary artery
ligation alone (A), or followed by 12 hours of reperfusion (B), or 24 hours of reperfusion (C).
Hearts were harvested for total protein which was assayed for cGMP hydrolytic activity. PDE5specific activity was measured as the sildenafil-inhibitable fraction of total cGMP hydrolysis,
normalized for total micrograms of protein, and trends to increase with both ischemia and I/R when
compared to the respective sham controls. Results are shown as means ± SEM (n=3-4; read in
duplicate).
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Figure 15: Ischemia and I/R do not affect cardiac pPDE5 expression in vivo.
Adult male ICR mice were subjected to 30 minutes of left anterior descending coronary
artery ligation alone (A), or followed by 12 hours of reperfusion (B), or 24 hours of
reperfusion (C). Following treatment hearts were harvested and equal amounts of whole
heart homogenate protein were resolved by SDS-PAGE and analyzed by western blotting
with antibody against pPDE5 (120 kDa). Blots were reprobed for α-Tubulin (55 kDa) to
demonstrate equal protein loading.
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Figure 16: Ischemia and I/R do not significantly affect cardiac pPDE5 protein
expression in vivo.
Adult male ICR mice were subjected to 30 minutes of left anterior descending coronary
artery ligation alone (A), or followed by 12 hours of reperfusion (B), or 24 hours of
reperfusion (C). Western blot densitometry measurements were calculated as a ratio of
pPDE5 to α-Tubulin which is not significantly changed by either ischemia or I/R when
compared to respective sham controls. Bar graphs represent the mean ± SEM.
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Figure 17: Ischemia and I/R do not affect cardiac pVASP expression in vivo.
Adult male ICR mice were subjected to 30 minutes of left anterior descending coronary
artery ligation alone (A), or followed by 12 hours of reperfusion (B), or 24 hours of
reperfusion (C). Following treatment hearts were harvested and equal amounts of whole
heart homogenate protein were resolved by SDS-PAGE and analyzed by western blotting
with antibody against pVASP (48 kDa). Blots were reprobed for total VASP (46 kDa) to
ensure that any changes in phosphorylation of VASP were not due to changes in its total
protein levels.
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Figure 18: Ischemia and I/R do not significantly affect cardiac pVASP protein
expression in vivo.
Adult male ICR mice were subjected to 30 minutes of left anterior descending coronary
artery ligation alone (A), or followed by 12 hours of reperfusion (B), or 24 hours of
reperfusion (C). Western blot densitometry measurements were calculated as a ratio of
pVASP to total VASP which is not significantly changed by either ischemia or I/R when
compared to respective sham controls. Bar graphs represent the mean ± SEM.
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Figure 19: Leakage of intracellular LDH due to I/R.
Adult male ICR mice hearts were isolated and subjected to 90 minutes of normoxic
perfusion, 30 minutes of global ischemia, or 30 minutes of global ischemia plus 30 minutes
of reperfusion. Leakage of LDH in heart effluent perfusate was measured before and after
the 30 minutes of global ischemia (except in the case of ischemia treatment alone, which
by definition lacks reperfusion measurement). Measurements of LDH activity were done
spectrophotometrically using a commercially available enzyme assay kit at 490 nm
wavelength (expressed as arbitrary unit, a.u./mL) and normalized against the individual
coronary flow rate (mL/min). Reperfusion of the isolated heart following ischemia caused
a significant increase in the leakage of LDH. Results are shown as means ± SEM.
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Figure 20: Ischemia and I/R upregulate cardiac expression of PDE5 ex vivo.
Adult male ICR mouse hearts were isolated and subjected to 90 minutes of normoxic
perfusion, or 30 minutes of global zero-flow ischemia, or 30 minutes of global zero-flow
ischemia plus 30 minutes of reperfusion in Langendorff mode. Following treatment hearts
were harvested and equal amounts of whole heart homogenate protein were resolved by
SDS-PAGE and analyzed by Western blotting with antibody against PDE5 (98 kDa).
Blots were reprobed for α-Tubulin (55 kDa) to demonstrate equal protein loading.
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Figure 21: Ischemia and I/R significantly increase cardiac PDE5 protein expression
ex vivo.
Adult male ICR mouse hearts were isolated and subjected to 90 minutes of normoxic
perfusion, 30 minutes of global ischemia, or 30 minutes of global ischemia plus 30 minutes
of reperfusion. Western blot densitometry measurements were calculated as a ratio of
PDE5 to α-Tubulin which is significantly increased by both ischemia and
ischemia/reperfusion when compared to respective normoxic perfusion controls. Bar
graphs represent the mean ± SEM.
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Figure 22: Ischemia and I/R trend to increase cardiac PDE5 protein activity ex vivo.
Adult male ICR mice hearts were isolated and subjected to 90 minutes of normoxic
perfusion, 30 minutes of global ischemia, or 30 minutes of global ischemia plus 30 minutes
of reperfusion. Hearts were harvested for total protein which was assayed for cGMP
hydrolytic activity. PDE5-specific activity was measured as the sildenafil-inhibitable
fraction of total cGMP hydrolysis, normalized for total micrograms of protein, and trends
to increase with both ischemia and reperfusion when compared to the respective control
normoxic perfusion group. Results are shown as means ± SEM (n=5; read in duplicate).
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Figure 23: Ischemia and I/R do not affect cardiac pPDE5 expression ex vivo.
Adult male ICR mice hearts were isolated and subjected to 90 minutes of normoxic
perfusion, 30 minutes of global ischemia, or 30 minutes of global ischemia plus 30 minutes
of reperfusion. Following treatment hearts were harvested and equal amounts of whole
heart homogenate protein were resolved by SDS-PAGE and analyzed by western blotting
with antibody against pPDE5 (120 kDa). Blots were reprobed for α-Tubulin (55 kDa) to
demonstrate equal protein loading.
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Figure 24: Ischemia and I/R do not significantly affect cardiac pPDE5 protein
expression ex vivo.
Adult male ICR mice hearts were isolated and subjected to 90 minutes of normoxic
perfusion, 30 minutes of global ischemia, or 30 minutes of global ischemia plus 30 minutes
of reperfusion. Western blot densitometry measurements were calculated as a ratio of
pPDE5 to α-Tubulin which is not significantly changed by either ischemia or
ischemia/reperfusion when compared to respective normoxic perfusion. Bar graphs
represent the mean ± SEM.
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Figure 25: Ischemia upregulates expression of cardic pVASP ex vivo which is
partially normalized by reperfusion.
Adult male ICR mouse hearts were isolated and subjected to 90 minutes of normoxic
perfusion as a control, 30 minutes of global ischemia (A), or 30 minutes of global ischemia
plus 30 minutes of reperfusion (B). Following treatment hearts were harvested and equal
amounts of whole heart homogenate protein were resolved by SDS-PAGE and analyzed by
western blotting with antibody against pVASP (48 kDa). Blots were reprobed for total
VASP (46 kDa) to ensure that any changes in phosphorylation of VASP were not due to
changes in its total protein levels.
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Figure 26: Ischemia significantly increases cardiac pVASP protein expression ex vivo
which is partially normalized by reperfusion.
Adult male ICR mouse hearts were isolated and subjected to 90 minutes of normoxic
perfusion as a control, 30 minutes of global ischemia (A), or 30 minutes of global ischemia
plus 30 minutes of reperfusion (B). Western blot densitometry measurements were
calculated as a ratio of pVASP to total VASP which is significantly increased following 30
minutes of ischemia when compared to respective normoxic perfusion (see Graph A). This
increase is partially abolished by 30 minutes of reperfusion (see Graph B). Bar graphs
represent the mean ± SEM.
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Figure 27: Leakage of intracellular LDH due to 10 minutes of ex vivo oxidant stress
with 100 µM H2O2 infusion.
Adult male ICR mice hearts were isolated and subjected to 60 minutes of normoxic
perfusion, or 10 minutes perfusion with 100 µM H2O2 followed by 30 minutes washout.
Leakage of LDH in heart effluent perfusate was measured before and after the 10 minutes
of perfusion with H2O2. Measurements of LDH activity were done spectrophotometrically
using a commercially available enzyme assay kit at 490 nm wavelength (expressed as
arbitrary unit, a.u./mL) and normalized against the individual coronary flow rate (mL/min).
10 min of H2O2 infusion did not cause a significant increase in the leakage of LDH.
Results are shown as means ± SEM.
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Figure 28: 10 minutes of ex vivo oxidant stress with 100 µM H2O2 does not affect
cardiac expression of PDE5.
Adult male ICR mice hearts were isolated and subjected to 60 minutes of normoxic
perfusion or 10 minutes of perfusion with the oxygen radical generator H2O2 (100 µM)
followed by 30 minutes of washout normoxic perfusion. Following treatment hearts were
harvested and equal amounts of whole heart homogenate protein were resolved by SDSPAGE and analyzed by western blotting with antibody against PDE5 (98 kDa). Blots were
reprobed for α-Tubulin (55 kDa) to demonstrate equal protein loading.
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Figure 29: 10 minutes of ex vivo oxidant stress with 100 µM H2O2 does not
significantly affect cardiac PDE5 protein expression.
Adult male ICR mice hearts were isolated and subjected to 60 minutes of normoxic
perfusion or 10 minutes of perfusion with 100 µM H2O2 followed by 30 minutes washout.
Western blot densitometry measurements were calculated as a ratio of PDE5 to α-Tubulin
which is not significantly changed following oxidant stress when compared to respective
normoxic perfusion control. Bar graphs represent the mean ± SEM.
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Figure 30: 10 minutes of ex vivo oxidant stress with 100 µM H2O2 does not affect
cardiac PDE5 activity.
Adult male ICR mice hearts were isolated and subjected to 60 minutes of normoxic
perfusion or 10 minutes of perfusion with 100 µM H2O2 followed by 30 minutes washout.
Hearts were harvested for total protein which was assayed for cGMP hydrolytic activity.
PDE5-specific activity was measured as the sildenafil-inhibitable fraction of total cGMP
hydrolysis, normalized for total micrograms of protein, and is not changed when compared
to the respective control normoxic perfusion group. Results are shown as means ± SEM
(n=6; read in duplicate).
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Figure 31: 10 minutes of ex vivo oxidant stress with 100 µM H2O2 does not affect
cardiac expression of pPDE5.
Adult male ICR mice hearts were isolated and subjected to 60 minutes of normoxic
perfusion or 10 minutes of perfusion with 100 µM H2O2 followed by 30 minutes washout.
Following treatment hearts were harvested and equal amounts of whole heart homogenate
protein were resolved by SDS-PAGE and analyzed by western blotting with antibody
against pPDE5 (120 kDa). Blots were reprobed for α-Tubulin (55 kDa) to demonstrate
equal protein loading.
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Figure 32: 10 minutes of ex vivo oxidant stress with 100 µM H2O2 does not
significantly affect cardiac pPDE5 protein expression.
Adult male ICR mice hearts were isolated and subjected to 60 minutes of normoxic
perfusion or 10 minutes of perfusion with 100 µM H2O2 followed by 30 minutes washout.
Western blot densitometry measurements were calculated as a ratio of pPDE5 to α-Tubulin
which is not changed following oxidant stress when compared to respective normoxic
perfusion controls. Bar graphs represent the mean ± SEM.
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Figure 33: 10 minutes of ex vivo oxidant stress with 100 µM H2O2 does not affect
cardiac expression of pVASP.
Adult male ICR mice hearts were isolated and subjected to 60 minutes of normoxic
perfusion or 10 minutes of perfusion with 100 µM H2O2 followed by 30 minutes washout.
Following treatment hearts were harvested and equal amounts of whole heart homogenate
protein were resolved by SDS-PAGE and analyzed by western blotting with antibody
against pVASP (48 kDa, upper band). Blots were reprobed for total VASP (46 kDa) to
ensure that any changes in phosphorylation of VASP were not due to changes in its total
protein levels.
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Figure 34: 10 minutes of ex vivo oxidant stress with 100 µM H2O2 does not
significantly affect cardiac pVASP protein expression.
Adult male ICR mice hearts were isolated and subjected to 60 minutes of normoxic
perfusion or 10 minutes of perfusion with 100 µM H2O2 followed by 30 minutes washout.
Western blot densitometry measurements were calculated as a ratio of pVASP to total
VASP which is not changed following oxidant stress when compared to respective
normoxic perfusion controls. Bar graphs represent the mean ± SEM.

65

Figure 35: Leakage of intracellular LDH due to 30 minutes of ex vivo oxidant stress
with 100 µM H2O2 infusion.
Adult male ICR mice hearts were isolated and subjected to 90 minutes of normoxic
perfusion, or 30 minutes perfusion with 100 µM H2O2 followed by 30 minutes washout.
Leakage of LDH in heart effluent perfusate was measured before and after the 30 minutes
of perfusion with H2O2. Measurements of LDH activity were done spectrophotometrically
using a commercially available enzyme assay kit at 490 nm wavelength (expressed as
arbitrary unit, a.u./mL) and normalized against the individual coronary flow rate (mL/min).
30 min of H2O2 infusion caused a significant increase in the leakage of LDH. Results are
shown as means ± SEM.
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Figure 36: 30 minutes of ex vivo oxidant stress with 100 µM H2O2 infusion does not
affect expression of PDE5.
Adult male ICR mice hearts were isolated and subjected to 90 minutes of normoxic
perfusion or 30 minutes of perfusion with 100 µM H2O2 followed by 30 minutes washout.
Following treatment hearts were harvested and equal amounts of whole heart homogenate
protein were resolved by SDS-PAGE and analyzed by Western blotting with antibody
against PDE5 (98 kDa). Blots were reprobed for α-Tubulin (55 kDa) to demonstrate equal
loading.
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Figure 37: 30 minutes of ex vivo oxidant stress with 100 µM H2O2 infusion does not
significantly affect PDE5 protein expression.
Adult male ICR mice hearts were isolated and subjected to 90 minutes of normoxic
perfusion or 30 minutes of perfusion with 100 µM H2O2 followed by 30 minutes washout.
Western blot densitometry measurements were calculated as a ratio of PDE5 to α-Tubulin
which is not changed following oxidant stress when compared to respective normoxic
perfusion controls. Bar graphs represent the mean ± SEM.
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Figure 38: 30 minutes of ex vivo oxidant stress with 100 µM H2O2 does not affect
cardiac PDE5 activity.
Adult male ICR mice hearts were isolated and subjected to 90 minutes of normoxic
perfusion or 30 minutes of perfusion with 100 µM H2O2 followed by 30 minutes washout.
Hearts were harvested for total protein which was assayed for cGMP hydrolytic activity.
PDE5-specific activity was measured as the sildenafil-inhibitable fraction of total cGMP
hydrolysis, normalized for total micrograms of protein, and is not changed when compared
to the respective control normoxic perfusion group. Results are shown as means ± SEM
(n=2; read in duplicate).

69

Figure 39: 30 minutes of ex vivo oxidant stress with 100 µM H2O2 does not affect
cardiac expression of pPDE5.
Adult male ICR mice hearts were isolated and subjected to 90 minutes of normoxic
perfusion or 30 minutes of perfusion with 100 µM H2O2 followed by 30 minutes washout.
Following treatment hearts were harvested and equal amounts of whole heart homogenate
protein were resolved by SDS-PAGE and analyzed by western blotting with antibody
against pPDE5 (120 kDa). Blots were reprobed for α-Tubulin (55 kDa) to demonstrate
equal protein loading.

70

Figure 40: 30 minutes of ex vivo oxidant stress with 100 µM H2O2 does not
significantly affect cardiac pPDE5 protein expression.
Adult male ICR mice hearts were isolated and subjected to 90 minutes of normoxic
perfusion or 30 minutes of perfusion with 100 µM H2O2 followed by 30 minutes washout.
Western blot densitometry measurements were calculated as a ratio of pPDE5 to α-Tubulin
which is not changed following oxidant stress when compared to respective normoxic
perfusion controls. Bar graphs represent the mean ± SEM.
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Figure 41: 30 minutes of ex vivo oxidant stress with 100 µM H2O2 infusion
upregulates expression of pVASP.
Adult male ICR mice hearts were isolated and subjected to 90 minutes of normoxic
perfusion or 30 minutes of perfusion with 100 µM H2O2 followed by 30 minutes washout.
Following treatment hearts were harvested and equal amounts of whole heart homogenate
protein were resolved by SDS-PAGE and analyzed by Western blotting with antibody
against pVASP (48 kDa). Blots were reprobed for total VASP (46 kDa) to ensure that any
changes in phosphorylation of VASP were not due to changes in its total protein levels.

72

Figure 42: 30 minutes of ex vivo oxidant stress with 100 µM H2O2 infusion
significantly increases cardiac pVASP protein expression.
Adult male ICR mice hearts were isolated and subjected to 90 minutes of normoxic
perfusion or 30 minutes of perfusion with 100 µM H2O2 followed by 30 minutes washout.
Western blot densitometry measurements were calculated as a ratio of pVASP to total
VASP which is significantly increased following oxidant stress when compared to
respective normoxic perfusion controls. Bar graphs represent the mean ± SEM.
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Experimental Protocol

PDE5
Expression

PDE5
Activity

in vivo I/R

pPDE5
pVASP
Expression Expression
—
—
—

ex vivo I/R
10 min. H2O2

—

—

—

30 min. H2O2

—

—

—

Table 1: Summary of experimental results

—
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Discussion
4.1 Rationale of the Present Study
The concept of pharmacological preconditioning with selective PDE5 inhibitors
protecting the heart against I/R injury was first introduced by Ockaili et al. in 2002 from
our laboratory.38 In that study and in a series of publications thereafter, our laboratory has
shown that this preconditioning-like cardioprotective effect against I/R involved
upregulation of eNOS and iNOS, activation of PKC/ERK, opening of mitochondrial KATP
channels, and attenuation of apoptosis by increasing the Bcl2/bax ratio.38,39,41-43 Still, as
diverse as these mechanisms are, none of these previous studies has shown a direct
involvement of PDE5 or relate to the known pharmacological action of sildenafil on
inhibiting PDE5. The purpose of the current investigation was to identify the role of PDE5
within the heart and specifically its response to cardiac ischemia/reperfusion injury. We
postulated that the detrimental events of ischemia and reperfusion lead to a deleterious
upregulation of PDE5 which is connected to the production of ROS and contributes to the
adverse cardiac stress response that follows myocardial infarction. Of particular interest
was defining PDE5 within the signaling mechanisms underlying the already proven
cardioproctective action of selective PDE5 inhibitors.
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4.2 Salient Findings
The major findings of this study are summarized as follows: 1. In vivo regional
ischemia and I/R increase the expression and trend to increase activity of PDE5 without
affecting PKG activity. 2. Ex vivo global ischemia and I/R increase the expression and
trend to increase activity of PDE5 as well as enhance PKG activity. 3. 10 minutes of ex
vivo oxidant stress had little to no effect upon PDE5 expression and activity as well as
PKG activity. 4. 30 minutes of ex vivo oxidant stress had little to no effect upon PDE5
expression and activity yet raised PKG activity. Taken together, these results provide the
first evidence that in acute cardiac ischemia and I/R, PDE5 upregulation may contribute to
a deleterious decline in cGMP and cytoprotective PKG signaling, potentially exacerbating
dysfunction. Additionally, there appears to be no connection between exposure to ROS
and the induction of PDE5. In fact, our data suggest two completely independent
mechanisms where PKG is induced by high levels of oxidant stress and PDE5 is induced
by the mediators other than ROS resulting from an ischemic event.
While our in vivo model shows both ischemia and I/R upregulate PDE5 with
downstream pVASP (an indicator of PKG activity) remaining unaltered, our ex vivo model
contrastingly shows a similar PDE5 upregulation but with a concordant downstream
increase in pVASP. This initially may seem paradoxical or contradictory, but the results
garnered from treatment with exogenous H2O2 lead to a logical explanation. 10 minutes of
oxidant stress resulted in no change in either PDE5 or pVASP expression, whereas 30
minutes of oxidant stress still resulted in no change in PDE5 but a dramatic increase in
pVASP expression. So, while low and high oxidant stress both had no effect on PDE5, it
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is only the high level of ROS that had a significant impact on PKG. Now the process
becomes clearer with respect to the ischemia models. In vivo, by ligation of the LAD, only
approximately 30 to 40% of the cardiomyocytes undergo ischemia. Ex vivo, the heart is
subjected to global zero-flow ischemia, and by definition 100% of the cardiomyocytes
undergo ischemia. So we believe that what is being witnessed within each of the models
can be considered under a “low” or “high” oxidant stress paradigm, respectively. The
lower number of ischemic cardiomyocytes in vivo produce less ROS leading to relatively
low oxidant stress, having no effect on PKG. The higher number of ischemic myocytes in
the ex vivo model produce much more ROS leading to high oxidant stress, which activates
PKG. Lastly, while both the in vivo and ex vivo hearts exhibited the increased PDE5 in
response to ischemia and I/R, neither low nor high levels of exogenous oxidant stress had
any effect on PDE5. Taken all together, this leads to the aforementioned speculation that
the upregulation of PDE5 is likely triggered via other mediators or factors following
ischemia and I/R, independent of exposure to the generated ROS (Fig. 43).
Overall a pathogenic PDE5 upregulation during ischemia and I/R may have an
important role in facilitating the acute stress response after AMI, as well as adverse
remodeling and functional impairment. Combined with data obtained from the previous
studies published by our group proving that PDE5 inhibition prior to AMI leads to a
dramatic reduction in infarct size in mice,39 these novel results mechanistically validate the
therapeutic strategies to combat this pathogenic PDE5 upregulation with selective PDE5
inhibitors.
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4.3 Upregulation of PDE5 triggered by in vivo ischemia and I/R
The presence of PDE5 within the heart has been a contentious issue with many
positive and negative findings.95-100 Recently, our lab was able to detect PDE5 expression
in the mouse heart and cardiomyocytes by RT-PCR, immunofluorescent staining, and
Western Blotting.43 Still, despite this discovery combined with other evidence of
myocardial PDE5 gene expression,69,101 its protein synthesis and enzyme activity are rather
low compared with other tissues such as lung, and have been traditionally thought to be
physiologically insignificant.99,102 In the current investigation, ICR mice underwent
regional AMI by LAD ligation and the hearts were analyzed for PDE5, pPDE5 and pVASP
expression as well as PDE5 activity. All three treatment groups (i.e. 30 min ischemia
alone, 30 min ischemia plus 12 hours or 24 hours of reperfusion) elicited a significant
upregulation of PDE5 protein when compared to their respective control sham operated
groups. In addition, we observed this upregulation of PDE5 protein surged immediately
following 30 minutes of ischemia, and there was a decrease at 12 hours of reperfusion
followed by a subsequent increase at 24 hours of reperfusion (Fig. 12, Fig. 13, Table 1).
This overall increase in PDE5 expression is scantily dealt with in the existing literature and
the factors leading to its occurrence are both poorly understood and intriguing. As stated
previously, we initially hypothesized it may be related to the production of ROS created
during ischemia and reperfusion, however our results suggest against this assumption
(Section 4.5). Still, ischemia and I/R injury set in motion a great number of signaling
cascades that could potentially be responsible for the phenomenon we observed. One
compelling possibility is angiotensin II (AngII), which has been shown to rapidly increase
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PDE5 mRNA and protein expression as well as PDE5 activity in vascular smooth
muscles.135 AngII is a powerful vasoconstrictor peptide that is proven to be produced
during ischemia.136-138 Furthermore, AngII can be produced endogenously in the heart.139
Hence it is conceivable that activation of AngII may play a role in upregulation of PDE5
and the resultant antagonization of cGMP signaling following myocardial ischemia.
Additionally, PDE5 upregulation could instead be attributed to NP (such as atrial
natriuretic peptide [ANP] and B-type natriuretic peptide [BNP]), which are known to be
released in response to myocardial ischemia. ANP and BNP levels are raised in patients in
the early phase of AMI.140 This increase in NP would then lead to an increase in pGC
activity, raising cGMP levels which then could cause PDE5 upregulation perhaps as a
feedback countering mechanism to trigger its breakdown in an attempt to maintain cGMP
levels within the physiological normal range in response to the insult of ischemia and I/R.
Furthermore, PDE5 has been shown to be phosphorylated in response to ANP, 141 however
this was not witnessed in our samples (Fig. 16, Table 1). These increased PDE5 levels
may relate to cGMP/PKG effects on transcription and posttranslational activation. Yet, the
increase we witnessed in PDE5 protein did not lead to an appreciable difference in
downstream PKG signaling, as evidenced by an insignificant change in pVASP protein,
whose phosphorylation is a direct product of PKG’s kinase activity (Fig. 18, Table 1). The
results additionally show that, while not significant, all three treatment groups trend to
cause an increase in PDE5 enzymatic activity (Fig. 14, Table 1). Thus, this clear
demonstration of PDE5 upregulation following cardiac ischemia and I/R suggests it may
contribute to a decline in cGMP and potential disruption of protective signaling in the
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heart. For example, PDE5 expression is reportedly increased in human and animal models
of right ventricular hypertrophy.107 This elevation did not translate to enhanced PKG
signaling when PDE5 inhibitors were applied. Increased PDE5 expression has also been
shown to predispose mice to adverse left ventricle remodeling after AMI.109

4.4 Upregulation of PDE5 triggered by ex vivo ischemia and I/R
In the current investigation, the hearts underwent ischemia and reperfusion in
isolated perfused Langendorff mode. The rationale for using the isolated heart model was
to eliminate all circulating factors that exist in vivo and demonstrate the direct effect of
ischemia and reperfusion on the expression and activity of PDE5 in the intact heart. The
hearts underwent global zero-flow ischemia and were analyzed for PDE5, pPDE5 and
pVASP expression as well as PDE5 activity. Both treatment groups (i.e. 30 min ischemia
alone, or 30 min ischemia plus 30 minutes of reperfusion), elicited an upregulation of
PDE5 protein when compared to their respective control 90 minutes of normoxic
perfusion. While both groups elicited an increase, the ischemia alone group yielded the
greater upregulation, which agrees with our in vivo experiments (Fig. 21, Table 1).
Interestingly, ischemia alone also concurrently increases downstream PKG signaling, as
evidenced by the significant increase in cardiac pVASP protein expression, which is then
partially normalized by subsequent reperfusion (Fig. 26, Table 1). The results additionally
show that both groups cause an increase in PDE5 enzymatic activity and suggest that,
while not significant, the increase due to I/R is greater than the increase following ischemia
alone (Fig. 22, Table 1). At first, we postulated the concordant increase in both the PDE5
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levels along with pVASP phosphorylation may be indicative of cGMP levels being
regulated by a PKG-dependent activation of PDE5. Specifically, an increase in cGMP
levels leads to triggering its breakdown by PDE5. At the same time, the activity of PDE5
is enhanced by PKG-dependent phosphorylation initiated by cGMP-specific binding to
allosteric sites on PDE5 in an attempt to maintain cGMP levels within the physiological
normal range in response to the insult of ischemia and I/R.142 Yet this phosphorylation
was not witnessed in our samples (Fig. 24, Table 1). As mentioned previously, while we
initially hypothesized that ROS production during ischemia and reperfusion may be related
to the PDE5 upregulation witnessed, we now believe that this oxidant stress is actually
directly affecting PKG independent of PDE5 upregulation. In this model, a great deal of
ROS are being produced by the global zero-flow ischemia of the Langendorff, whereby
100% of the cardiomyocytes undergo ischemia. We believe this high level of oxidant
stress is directly activating PKG and causing the high levels of pVASP expression (Section
4.5). The partial normalization of pVASP expression following reperfusion is likely a
result of washout of the ROS produced during ischemia and upon reperfusion.

4.5 Effect of exposure to exogenous H2O2 on PDE5
Heart ischemia is known to induce increased generation of ROS, and subsequent
reperfusion can result in toxic ROS overproduction that possibly contributes to irreversible
damage of mitochondrial function and consequently impaired recovery of physiological
function and cell death.125-129 In the current investigation, the hearts underwent oxidant
stress in isolated perfused Langendorff mode to demonstrate the direct effect of exposure
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to ROS on the expression and activity of PDE5 in the intact heart without any circulating
confounders that exist in vivo. Following 10 minutes of perfusion with the oxygen radical
generator H2O2 (100 µM) followed by 30 minutes of washout normoxic perfusion, the
hearts were analyzed for PDE5, pPDE5 and pVASP expression as well as PDE5 activity.
The results showed that 10 minutes of oxidant stress had little effect on the amount of
PDE5 or pPDE5 protein when compared to the respective control 60 minutes of normoxic
perfusion (Fig. 29, Fig. 31, & Table 1). This same treatment also left downstream PKG
signaling unaltered, as evidenced by the unaffected levels of cardiac pVASP protein
expression (Fig. 34, Table 1). The results further suggest that a short duration of ROS
exposure results in little to no increase in PDE5 enzymatic activity (Fig. 30, Table 1).
Some have purported a possible interaction between ROS and PDE5 may potentially lie in
the fact that promoter analysis shows both a Sp-1 and an activator protein-1 (AP-1) site in
the human PDE5 promoter region.143 Both of these transcription factors have been shown
to be redox sensitive and are claimed to represent potential downstream targets of ROSmediated signaling on PDE5.144 However, they are also downstream targets of AngII as
well and, as mentioned, this could be a potential mediator of PDE5 upregulation. Farrow
et al. have reported that treatment of FPASMCs with exogenous H2O2 leads to a significant
upregulation of PDE5.131 Reconciling this with our results may lie in the models
themselves. Farrow et al. utilized isolated FPASMCs while we investigated adult whole
heart homogenates. Not only were entirely different cell types being studied, but it is
possible that ROS have a much different effect on isolated cells when compared to
exposure via intra-coronary perfusion of an entire organ. Lu et al. have reported that
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myocardial PDE5 expression is increased in CHF along with oxidative stress markers and
that this increase is blunted by a SOD mimetic.110 However the approach in this study also
differs greatly from our own. Lu et al. implemented a protocol of chronic TAC induced
CHF while we instead looked at the much more acute model of I/R and exogenous
administration of H2O2. Ultimately, ROS is a very general effecter of many transcription
factors and the presence of Sp-1 and AP-1 promoter sites in the PDE5A gene does not
implicate a direct connection. Oxidative stress can broadly affect many signaling
pathways by altering the expression and modification of many important molecules. A
precise molecular mechanism by which oxidative stress can regulate PDE5 expression has
not been defined and our results indicate that such a potential link does not sufficiently
lead to the induction of PDE5, and this induction instead occurs via other mediating factors
independent of ROS.
Further emphasizing this point, additional hearts were subjected to 30 minutes of
H2O2 (100 µM) perfusion followed by 30 minutes of washout normoxic perfusion, and
again analyzed for PDE5, pPDE5 and pVASP expression as well as PDE5 activity. The
longer duration of oxidant stress had little effect on the amount of PDE5 or pPDE5 protein
when compared to the respective control 90 minutes of normoxic perfusion (Fig. 37, Fig.
40, & Table 1). However, this treatment did lead to an increase in downstream PKG
signaling, as evidenced by the significantly higher levels of cardiac pVASP protein
expression (Fig. 42, Table 1). The results additionally suggested that a long duration of
ROS exposure results in unchanged PDE5 enzymatic activity (Fig. 38, Table 1). This
result, given the longer exposure to oxidative stress, again underscores the lack of a

83
connection between ROS and PDE5. However, there is a growing body of literature
showing PKG is regulated by cellular redox status.145,146 In fact, it was recently shown that
oxidation of PKG by exogenous H2O2 directly activated PKG and this oxidation-induced
activation indicates an alternate mechanism for its regulation independent of the classical
activation via cGMP.147 Thus, it is likely that the observed induction of PKG following 30
minutes of oxidative stress is proceeding through this mechanism and it appears the
oxidation-induced activation is time dependent with respect to exposure duration to H2O2,
given that 10 minutes of oxidative stress produced little change in cardiac pVASP
expression.

4.6 Future Studies
More work is needed to better elucidate the pathophysiologic conditions under
which PDE5 upregulation occurs as well as the principal mediating factors involved (e.g.
by using AngII receptor blockers). Additional investigations are also required to further
demonstrate the lack of a relationship between ROS and PDE5. This would be
accomplished by monitoring PDE5 and pVASP levels following administration of
antioxidants such as N-2-mercaptopropionyl glycine (MPG) to the hearts subjected to
ischemia and I/R in the isolated perfused heart model. According to our current theory,
PKG activity would be blocked by antioxidants while PDE5 upregulation still present,
providing a more definitive illustration of two separate mechanisms at work. Furthermore,
it would be highly valuable to reproduce the current results within isolated ventricular
cardiomyocytes themselves to demonstrate the cell type specificity.
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4.7 Conclusions and Translational Perspectives
It is paramount to recognize that practicing preventative medicine will most
effectively control the prevalence and persistence of heart disease and specifically
myocardial infarction in our country. However, limitations such as access, availability,
education, and other socioeconomic factors of medical care often impair this approach.
Therefore, a clinical challenge exists in finding therapeutic strategies to limit and reduce
ischemic insult, thus preserving heart function. Novel medical treatments that will
effectively limit the extent of tissue damage caused by myocardial infarction are urgently
needed. Identifying mechanisms of endogenous cellular protection or tolerance against
ischemia is coming to the forefront of research in order to find new methods for treating
cardiovascular diseases. This study acknowledges that fact and identifies PDE5 as a valid
and novel target to combat the detrimental effects of a heart attack.
Our present studies have provided the first evidence that cardiac PDE5
upregulation, occurring as a result of infarction, is independent of oxidant stress and it may
contribute to a deleterious decline in cGMP and a potential disruption of protective
signaling in the ischemic heart. The discovery of this pathogenic PDE5 upregulation that
occurs following ischemia and I/R further augments and mechanistically validates the
argument for therapeutic strategies utilizing selective PDE5 inhibitors in the fight against
irreversible heart attack damage. We have witnessed a seemingly ever growing pandemic
of heart disease and heart attacks in our country today. Often we are hard pressed to find
anyone who has not had a relative or significant other affected by these diseases. Yet the
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observations contained within this study help in identifying a novel target for treatment and
I am excited that amid growing interest combined with dedication, we may look forward to
major strides being taken during our lifetime toward making sure further life is not lost.
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Figure 43: Summary of ROS-independent upregulation of PDE5 in the ischemic
heart.
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